



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA
DIPARTIMENTO DI MEDICINA SPECIALISTICA
DIAGNOSTICA E SPERIMENTALE

POLICLINICO DI
SANT'ORSOLA



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Bologna

New Drugs in Hematology

President: Pier Luigi Zinzani

Co-President: Michele Cavo

Honorary President: Sante Tura

**Bologna,
Royal Hotel Carlton**

October 1-3, 2018

BOLOGNA

BOLOGNA, ROYAL HOTEL CARLTON

Auspices

ALMA MATER STUDIORUM
UNIVERSITÀ DEGLI STUDI DI BOLOGNA

REGIONE EMILIA-ROMAGNA

AZIENDA OSPEDALIERO-UNIVERSITARIA
DI BOLOGNA

AIL ASSOCIAZIONE ITALIANA CONTRO
LE LEUCEMIE - LINFOMI E MIELOMA

SEZIONE DI BOLOGNA

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA



FACULTY

Ranjana	Advani	Stanford, USA	John	Kuruvilla	Toronto, Canada
Stephen M.	Ansell	Rochester, USA	Mark	Levis	Baltimore, USA
Andrea	Artoni	Milan, Italy	Giovanni	Martinelli	Bologna, Italy
Michele	Baccarani	Bologna, Italy	Anthony R.	Mato	New York, USA
Andrea	Bacigalupo	Rome, Italy	Philippe	Moreau	Nantes, France
Nizar J.	Bahlis	Calgary, Canada	Alison J.	Moskowitz	New York, USA
Ivan	Borrello	Baltimore, USA	Craig H.	Moskowitz	New York, USA
Massimo	Breccia	Rome, Italy	Sattva S.	Neelapu	Houston, USA
Tim H.	Brummendorf	Aachen, Germany	Susan M.	O'Brien	Irvine, USA
Lars	Bullinger	Berlin, Germany	Owen A.	O'Connor	New York, USA
Christian	Buske	Ulm, Germany	Michinori	Ogura	Kasugai City, Japan
John	Byrd	Columbus, USA	Fabrizio	Pane	Naples, Italy
Michele	Cavo	Bologna, Italy	Cristina	Papayannidis	Bologna, Italy
Robert	Chen	Duarte, USA	Francesco	Passamonti	Varese, Italy
Bruce D.	Cheson	Washington, USA	Ruth	Pettengell	London, United Kingdom
Paolo	Corradini	Milan, Italy	Vincent	Ribrag	Villejuif, France
Jorge E.	Cortes	Houston, USA	Paul G.	Richardson	Boston, USA
Antonio	Cuneo	Ferrara, Italy	Davide	Rossi	Bellinzona, Switzerland
Ian	Flinn	Nashville, USA	Gianantonio	Rosti	Bologna, Italy
Robin	Foà	Rome, Italy	Simon	Rule	Plymouth, United Kingdom
Andres	Forero-Torres	Birmingham, USA	Laurie H.	Sehn	Vancouver, Canada
Nathan H.	Fowler	Houston, USA	John F.	Seymour	Melbourne, Australia
Francesco	Galimi	Thousand Oaks, USA	Michele	Spina	Aviano, Italy
Leo I	Gordon	Chicago, USA	Luis Michael	Staudt	Bethesda, USA
John	Gribben	London, United Kingdom	Juan Louis	Steegmann	Madrid, Spain
Claire	Harrison	London, United Kingdom	Constantine	Tam	Melbourne, Australia
Elias	Jabbour	Houston, USA	Ayalew	Tefferi	Rochester, USA
Joseph G.	Jurcic	New York, USA	Alessandro M.	Vannucchi	Florence, Italy
Wojciech	Jurczak	Kraków, Poland	Ravi	Vij	St. Louis, USA
Jean Jacques	Kiladjian	Paris, France	Umberto	Vitolo	Turin, Italy
Arne	Kolstad	Oslo, Norway	Anas	Younes	New York, USA
Marina	Konopleva	Houston, USA	Andrew D.	Zelenez	New York, USA
Shaji K.	Kumar	Rochester, USA	Pier Luigi	Zinzani	Bologna, Italy

Monday, October 1, 2018

9.00 a.m. *Welcome and Introduction*

Three recent “impressive” stories

Chairman: *P. Corradini*

9.15 a.m. Checkpoint inhibitors - *A. Younes*

9.40 a.m. Daratumumab - *M. Cavo*

10.05 a.m. CAR T-cells - *S.S. Neelapu*

Session I: Classical Ph1-neg myeloproliferative neoplasms

Chairmen: *F. Passamonti, A.M. Vannucchi*

10.45 a.m. Status of the art of treatment - *C. Harrison*

11.05 a.m. Ruxolitinib in myelofibrosis - *F. Passamonti*

11.20 a.m. Ruxolitinib in polycitemia vera - *A.M. Vannucchi*

11.35 a.m. Interferons in MPNs - *J.J. Kiladjian*

11.50 a.m. New drugs and combination therapy - *A. Tefferi*

12.05 p.m. Allograft in myelofibrosis - *A. Bacigalupo*

12.30 p.m. **Lunch**

Session II: Hodgkin's lymphoma

Chairmen: *A. Younes, P.L. Zinzani*

1.30 p.m. Status of the art of treatment - *A. Younes*

1.50 p.m. Nivolumab - *A. Younes*

2.05 p.m. Pembrolizumab - *R. Chen*

2.20 p.m. Brentuximab vedotin - *A.J. Moskowitz*

2.35 p.m. New Combo-steps - *S.M. Ansell*

Focus on: Prognostic factor and prediction of response in lymphoma

Chairman: *B.D. Cheson*

2.55 p.m. Molecular predictors of response - *L.M. Staudt*

3.15 p.m. Can we use imaging to predict response? - *C.H. Moskowitz*

3.35 p.m. Role of circulating tumor DNA in response prediction and assessment of clonal evolution - *D. Rossi*

SESSION III: Acute leukemia

Chairmen: *M. Levis, G. Martinelli*

4.00 p.m. Status of the art: from genomic knowledge to target therapy in leukemias - *L. Bullinger*

4.20 p.m. Gliteritinib - *M. Levis*

4.35 p.m. Quizartinib - *J.E. Cortes*

4.50 p.m. SY-1425 - *J.G. Jurcic*

5.05 p.m. Inotuzumab in ALL - *E. Jabbour*


5.20 p.m. Venetoclax - *M. Konopleva*

5.35 p.m. Idasanutlin - *C. Papayannidis*

5.50 p.m. Ponatinib - *E. Jabbour*

6.05 p.m. MCL1 inhibitors - *F. Galimi*

6.20 p.m. Blinatumumab in Ph+ and Ph neg ALL - *R. Foà*



SESSION IV: Non-Hodgkin's lymphoma (I)

Chairmen: S.M. Ansell, O.A. O'Connor

- 8.30 a.m.** Status of the art of treatment - *S.M. Ansell*
8.50 a.m. Obinutuzumab - *L.H. Sehn*
9.05 a.m. MOR208 - *W. Jurczak*
9.15 a.m. Polatuzumab - *R. Advani*
9.30 a.m. Mogamulizumab - *M. Ogura*
9.45 a.m. CC-122 - *V. Ribrag*
10.00 a.m. EDO-S101 - *O.A. O'Connor*
10.15 a.m. Selinexor - *J. Kuruvilla*
10.30 a.m. Pixantrone - *R. Pettengell*

11.00 a.m. Coffee break

Session V: Chronic Lymphocitic Leukemia

Chairmen: A. Cuneo, R. Foà

- 11.15 a.m.** Status of the art of management - *S.M. O'Brien*
11.35 a.m. Ibrutinib - *J. Byrd*
11.50 a.m. Idelalisib - *A.D. Zelenetz*
12.05 p.m. Venetoclax - *J. Seymour*
12.20 p.m. Acalabrutinib - *J. Byrd*
12.35 p.m. BGB-3111 - *C. Tam*
12.50 p.m. TGR-1202 - *J. Gribben*

1.15 p.m. Lunch

Focus on: "the old, the new and the future in the same drug"


Chairman: M. Spina

- 2.15 p.m.** Bendamustine - *B.D. Cheson*
2.35 p.m. Lenalidomide - *N.H. Fowler*
2.55 p.m. Rituximab biosimilars - *C. Buske*
3.15 p.m. Umbralisib (TGR-1202) - *A.R. Mato*

SESSION VI: Non-Hodgkin's lymphoma (II)

Chairmen: N.H. Fowler, U. Vitolo

- 3.50 p.m.** Venetoclax - *S. Rule*
4.05 p.m. Idelalisib - *S.M. Ansell*
4.20 p.m. Umbralisib - *O.A. O'Connor*
4.35 p.m. Copanlisib - *P.L. Zinzani*
4.50 p.m. Duvelisib - *I. Flinn*
5.05 p.m. INCB050465 - *A. Forero-Torres*
5.20 p.m. ME-401 - *A. Zelenetz*
5.35 p.m. Acalabrutinib - *S. Rule*
5.50 p.m. BGB-3111 - *C. Tam*
6.05 p.m. Tazemetostat - *V. Ribrag*
6.20 p.m. TAK-659 - *L.I. Gordon*
6.35 p.m. Betalutin - *A. Kolstad*



Wednesday, October 3, 2018

8.30 a.m. Lecture

Thrombotic thrombocytopenic purpura: a look at the future - *A. Artoni*

SESSION VII: Multiple myeloma

Chairmen: *M. Cavo, P.G. Richardson*

8.50 a.m. New proteasome inhibitors (Oprozomib, Marizomib) - *P.G. Richardson*

9.10 a.m. Selinexor - *N. Bahlis*

9.30 a.m. Venetoclax - *P. Moreau*

9.50 a.m. Monoclonal antibodies: Isatuximab, MOR202 - *S.K. Kumar*

10.10 a.m. Monoclonal antibodies and BTKs: anti-PD-1/PDL-1, Ibrutinib - *R. Vij*

SESSION VIII: Chronic myeloid leukemia

Chairmen: *F. Pane, G. Rosti*

10.45 a.m. Bosutinib - *T.H. Brummendorf*

11.05 a.m. CAR-T and other immunotherapies - *I. Borrello*


11.20 a.m. Imatinib, nilotinib and dasatinib frontline:
which and why? - *J.L. Steegmann*

11.35 a.m. ABI001 and combination - *M. Breccia*

11.50 a.m. Ponatinib - *M. Baccarani*

12.05 p.m. Treatment free remission - *G. Rosti*

12.25 p.m. Conclusions and Arrivederci



GENERAL INFORMATION

MEETING VENUE

Royal Hotel Carlton

Via Montebello, 8 - 40121 Bologna, Italy
Phone +39 051 249361 - Fax +39 051 249724
www.royalhotelcarltonbologna.com

OFFICIAL LANGUAGE

English

REGISTRATION FEE

Euro 400,00 (Italian VAT included)

The registration fee includes: conference kit, participation in the scientific sessions, attendance certificate, coffee breaks, lunch, slides of the meeting.

BADGE

All registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions.

ATTENDANCE CERTIFICATE

A certificate will be given to all participants at the end of the meeting.

ITALIAN CME CREDITS

A request for Italian CME credits have been made as follows:

- Provider Studio ER Congressi SRL: ID 828-213626.
- No. **6 CME** credits for physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology), biologists and chemists.
- Educational objective: “guidelines-protocols-procedures”.

EUROPEAN CME CREDITS

The program of the “New Drugs in Hematology” has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 22 CME credits for Physicians, biologists and chimists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org> even on site.

CHANGES

Parts of the program may be changed without notice.

New Drugs in Hematology

Scientific Secretariat

Pier Luigi Zinzani

Istituto di Ematologia

“Lorenzo e Ariosto Seràgnoli”

Via Massarenti, 9 - 40138 Bologna, Italy

Phone +39 051 6363680 - Fax +39 051 6364037

e-mail: pierluigi.zinzani@unibo.it

Organizing Secretariat

Studio E.R. Congressi

Via Marconi, 36 - 40122 Bologna, Italy

Phone +39 051 4210559 - Fax +39 051 4210174

e-mail: ercongressi@ercongressi.it

www.ercongressi.it